New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
06:35 EDTVICLVical reports Q4 EPS (9c), consensus (10c)
Reports Q4 revenue $2.32M, consensus $1.64M.
News For VICL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 23, 2015
11:00 EDTVICLVical downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
09:14 EDTVICLOn The Fly: Pre-market Movers
Subscribe for More Information
June 22, 2015
19:00 EDTVICLOn The Fly: After Hours Movers
Subscribe for More Information
17:08 EDTVICLVical down 45% after herpes vaccine study fails to meet primary endpoint
Subscribe for More Information
16:12 EDTVICLVical reports top-line results from Phase 1/2 trial of genital herpes vaccine
Vical announced top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2, or HSV-2, infected patients. The trial enrolled patients across seven U.S. sites and is evaluating two constructs: a monovalent, or gD, vaccine and a bivalent, or gD + UL46, vaccine, each formulated with Vical's proprietary Vaxfectin adjuvant. The top-line analysis compared pre-vaccination measurements for each arm with those taken during the swabbing period in months 2 and 3 following the last vaccine dose. Neither the monovalent nor bivalent vaccine met the primary endpoint. On prospectively defined secondary endpoints, the bivalent vaccine achieved statistically significant reductions in the rate of genital lesions and viral load from positive swabs versus baseline. Both the monovalent and bivalent vaccines were generally well tolerated. Safety data have been reviewed throughout the trial by an independent safety monitoring board, and no grade 4 adverse events or serious adverse events related to vaccination have been observed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use